https://orcid.org/0000-0002-8921-7438
References
- Lymphoma Research Foundation. Diffuse large B-cell lymphoma: treatment options [Internet]. [cited 2021 Jan 9]. Available from: https://lymphoma.org/aboutlymphoma/nhl/dlbcl/dlbcltreatment/
- NIH National Cancer Institute. Cancer stat facts: NHL – diffuse large B-cell lymphoma (DLBCL) [Internet]. [cited 2021 Jan 8]. Available from: https://seer.cancer.gov/statfacts/html/dlbcl.html
- American Cancer Society. Survival rates and factors that affect prognosis (outlook) for non-Hodgkin lymphoma [Internet]. [cited 2021 Jan 08]. Available from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/factors-prognosis.html
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
- Raut LS, et al. Management of relapsed-refractory diffuse large B cell lymphoma South Asian. J Cancer. 2014;3(1):66–70.
- Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616.
- Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
- Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31(3):209–216.
- Hitz F, Connors JM, Gascoyne RD, et al. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Ann Hematol. 2015;94(11):1839–1843.
- Skrabek P, Assouline S, Christofides A, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol. 2019;26(4):253–265.
- Thuresson P-O, Vander Velde N, Gupta P, et al. A systematic review of the clinical efficacy of treatments in relapsed or refractory diffuse large B cell lymphoma. Adv Ther. 2020;37(12):4877–4893.
- FDA. FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma [Internet]. [cited 2021 Jan 7]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma
- FDA. FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma [Internet]. [cited 2021 Jan 5]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma
- Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
- Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in RR DLBCL (L-MIND). Lancet Oncol. 2020;21(7):978–988.
- Kim H, Gurrin L, Ademi Z, et al. Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data. Br J Clin Pharmacol. 2014;77(1):116–121.
- R Studio. Boston (MA): PBC.
- Redbook [Internet]. [cited 2020 Oct–Nov]. Available through the University of Arizona Library from: https://www.micromedexsolutions.com.ezproxy4.library.arizona.edu/micromedex2/librarian/ssl/true
- CMS. Physician fee schedule search [Internet]. [cited 2020 Oct]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched
- Quest Diagnostics. All available tests [Internet]. [cited 2020 Nov]. Available from: https://questdirect.questdiagnostics.com/products?category=All
- Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLOS One. 2018;13(4):e0196007.
- Zhand X, et al. Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States. Expert Rev Pharmacoecon Outcomes Res. 2018;18(5):573–580.
- CEA Registry. Center for the evaluation of value and risk in health [Internet]. [cited 2020 Oct 27]. Available from: http://healtheconomicsdev.tuftsmedicalcenter.org/cear2/search/search.aspx
- Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146(2):164–170.
- Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–2132.
- United States Department of Labour. BLS Data Labs, inpatient hospital services in U.S [Internet]. [cited 2020 Nov 28]. Available from: https://beta.bls.gov/dataViewer/view/timeseries/CUUR0000SS5702
- Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–178.
- Neumann PJ. Using cost–effectiveness. Analysis to improve health care. New York (NY): Oxford University Press; 2005.
- Neumann PJ, Cohen JT, Weinstein MC, et al. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
- Klarman HE, et al. Cost effectiveness analysis applied to the treatment of chronic renal disease. Med Care. 1968;6(1):48–54.
- Braithwaite RS, Meltzer DO, King JT, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule. Med Care. 2008;46(4):349–356.